- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Reference genome.
Displaying page 1 of 1.
EudraCT Number: 2005-003041-14 | Sponsor Protocol Number: 565 | Start Date*: 2005-09-20 |
Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna | ||
Full Title: Anti-inflammatory effect of statins in the human endotoxin model | ||
Medical condition: Healthy volunteers are tested in an endotoxemia model | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005036-28 | Sponsor Protocol Number: 2012/41 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:CENTRE ANTOINE LACASSAGNE | |||||||||||||
Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate | |||||||||||||
Medical condition: Prostate cancer metastatic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004418-17 | Sponsor Protocol Number: I-BCT-1 | Start Date*: 2014-05-07 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens. | ||
Medical condition: breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002917-30 | Sponsor Protocol Number: CARCINOSIS | Start Date*: 2015-09-10 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Assessment of histopathological response to combination chemotherapy with Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in patients with peritoneal metastasis from colorectal cancer (CARCIN... | ||||||||||||||||||
Medical condition: Patients with peritoneal carcinomatosis from colorectal cancer are treated with a combination chemotherapy (FOLFOXIRI+ Bevacizumab) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005177-21 | Sponsor Protocol Number: HGS1006-C1056 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) SE (Completed) NL (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002809-48 | Sponsor Protocol Number: CRO782 | Start Date*: 2013-04-17 | |||||||||||
Sponsor Name:Imperial College London and Imperial College Healthcare NHS Trust | |||||||||||||
Full Title: Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device | |||||||||||||
Medical condition: Advanced heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001755-31 | Sponsor Protocol Number: NCT-2017-0417 | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty | |||||||||||||
Full Title: Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies | |||||||||||||
Medical condition: Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005266-34 | Sponsor Protocol Number: UX701-CL301 | Start Date*: 2022-02-11 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Dis... | |||||||||||||
Medical condition: Wilson disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001641-79 | Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001696-22 | Sponsor Protocol Number: 64041575MPN2001 | Start Date*: 2018-06-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine ... | |||||||||||||
Medical condition: Human metapneumovirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Temporarily Halted) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001653-40 | Sponsor Protocol Number: 64041575RSV2003 | Start Date*: 2016-12-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002761-33 | Sponsor Protocol Number: R3918-PNH-2022 | Start Date*: 2022-05-02 | |||||||||||
Sponsor Name:REGENERON PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGL... | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) PL (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004486-40 | Sponsor Protocol Number: R3918-PNH-2021 | Start Date*: 2022-04-04 | |||||||||||
Sponsor Name:REGENERON PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A... | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002302-39 | Sponsor Protocol Number: RSV-M-301 | Start Date*: 2016-09-06 | |||||||||||
Sponsor Name:Novavax, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Alumi... | |||||||||||||
Medical condition: Respiratory syncytial virus (RSV) is the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide. In industrialized countries, nearly all children have... | |||||||||||||
|
|||||||||||||
Population Age: In utero, Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
